Upgrade todayGoldman Sachs upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $170.00 (from $111.00). Analyst Navdeep Singh noted ibrutinib launch as checks indicate strong uptake and he thinks the drug has potential of $7.5 billion.